Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer

Abstract. Background:. Accumulating evidence have revealed that pretreatment albumin to globulin ratio (AGR) may be a predictor of prognosis among patients with colorectal cancer (CRC). However, these findings are inconsistent. The aim of the present study was to investigate the prognostic value of...

Full description

Bibliographic Details
Main Authors: Jian-Ying Ma, MD, Gang Liu, MD, Liang-Zhi Pan, MD, Min Hu, MD, Zhong-Zhong Zhu, MD, Christine Pocha.
Format: Article
Language:English
Published: Wolters Kluwer 2022-05-01
Series:Medicine
Online Access:http://journals.lww.com/10.1097/MD.0000000000029190
_version_ 1811256521380593664
author Jian-Ying Ma, MD
Gang Liu, MD
Liang-Zhi Pan, MD
Min Hu, MD
Zhong-Zhong Zhu, MD
Christine Pocha.
author_facet Jian-Ying Ma, MD
Gang Liu, MD
Liang-Zhi Pan, MD
Min Hu, MD
Zhong-Zhong Zhu, MD
Christine Pocha.
author_sort Jian-Ying Ma, MD
collection DOAJ
description Abstract. Background:. Accumulating evidence have revealed that pretreatment albumin to globulin ratio (AGR) may be a predictor of prognosis among patients with colorectal cancer (CRC). However, these findings are inconsistent. The aim of the present study was to investigate the prognostic value of pretreatment AGR in CRC. Methods:. A systematic meta-analysis was conducted by searching MEDLINE, EMBASE, and Cochrane Library databases. Results:. A total of 9 studies with 7939 patients were finally included. Low pretreatment AGR was associated with worse overall survival (pooled hazard ratio [HR]: 2.07, 95% CI: 1.60–2.67, P < .001) and disease-free survival/progress-free survival (pooled hazard ratio [HR]: 2.10, 95% confidence interval [CI]: 1.34–3.31, P = .001). Subgroup analyses revealed that the pooled correlation did not alter these results. Moreover, low pretreatment AGR were associated with elderly patients, tumor diameter (≥50 mm), tumor node metastasis stage (III–IV), depth of tumor (T3–4), and CA19-9 (>37 U/mL). Conclusion:. The present meta-analysis suggests that low pretreatment AGR was associated with advanced clinicopathological features and worse prognosis, suggesting AGR is a useful prognostic biomarker for CRC patients.
first_indexed 2024-04-12T17:41:27Z
format Article
id doaj.art-6431d67b8fac4dafb3b52dd7024e8c70
institution Directory Open Access Journal
issn 0025-7974
1536-5964
language English
last_indexed 2024-04-12T17:41:27Z
publishDate 2022-05-01
publisher Wolters Kluwer
record_format Article
series Medicine
spelling doaj.art-6431d67b8fac4dafb3b52dd7024e8c702022-12-22T03:22:47ZengWolters KluwerMedicine0025-79741536-59642022-05-0110120e2919010.1097/MD.0000000000029190202205200-00011Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancerJian-Ying Ma, MDGang Liu, MDLiang-Zhi Pan, MDMin Hu, MDZhong-Zhong Zhu, MDChristine Pocha.Abstract. Background:. Accumulating evidence have revealed that pretreatment albumin to globulin ratio (AGR) may be a predictor of prognosis among patients with colorectal cancer (CRC). However, these findings are inconsistent. The aim of the present study was to investigate the prognostic value of pretreatment AGR in CRC. Methods:. A systematic meta-analysis was conducted by searching MEDLINE, EMBASE, and Cochrane Library databases. Results:. A total of 9 studies with 7939 patients were finally included. Low pretreatment AGR was associated with worse overall survival (pooled hazard ratio [HR]: 2.07, 95% CI: 1.60–2.67, P < .001) and disease-free survival/progress-free survival (pooled hazard ratio [HR]: 2.10, 95% confidence interval [CI]: 1.34–3.31, P = .001). Subgroup analyses revealed that the pooled correlation did not alter these results. Moreover, low pretreatment AGR were associated with elderly patients, tumor diameter (≥50 mm), tumor node metastasis stage (III–IV), depth of tumor (T3–4), and CA19-9 (>37 U/mL). Conclusion:. The present meta-analysis suggests that low pretreatment AGR was associated with advanced clinicopathological features and worse prognosis, suggesting AGR is a useful prognostic biomarker for CRC patients.http://journals.lww.com/10.1097/MD.0000000000029190
spellingShingle Jian-Ying Ma, MD
Gang Liu, MD
Liang-Zhi Pan, MD
Min Hu, MD
Zhong-Zhong Zhu, MD
Christine Pocha.
Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
Medicine
title Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
title_full Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
title_fullStr Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
title_full_unstemmed Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
title_short Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer
title_sort clinical impact of pretreatment albumin globulin ratio in patients with colorectal cancer
url http://journals.lww.com/10.1097/MD.0000000000029190
work_keys_str_mv AT jianyingmamd clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer
AT gangliumd clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer
AT liangzhipanmd clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer
AT minhumd clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer
AT zhongzhongzhumd clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer
AT christinepocha clinicalimpactofpretreatmentalbuminglobulinratioinpatientswithcolorectalcancer